Drug Approval | August 09, 2025
Zydus receives final approval from USFDA for Prucalopride Tablets
Prucalopride is prescribed for chronic idiopathic constipation
Prucalopride is prescribed for chronic idiopathic constipation
This is the group’s first NoC approval in Canada
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Celecoxib is a nonsteroidal anti-inflammatory drug
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)
Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer
Eluxadoline is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhoea
Subscribe To Our Newsletter & Stay Updated
